The study is also evaluating ABBV-400 with bevacizumab in pts with CRC.Clinical trial information: NCT05029882.Preliminary efficacy outcomes.CRC Dosing Cohorts1.6 mg/kg Q3W(n = 32)2.4 mg/kg Q3W(n = 40)3.0 mg/kg Q3W(n = 41)Confirmed ORR, n (%)06 (15)8 (20)CBR12, n (%)11 (...
原始出处:AbbVie Initiates Phase 2 Clinical Trial Programs for ABBV-8E12, an Investigational Anti-Tau Antibody, in Early Alzheimer's Disease and Progressive Supranuclear Palsy
We're also making good progress with our next-generation c-Met ADC ABBV-400, which utilizes the same c-Met blocking antibody as Teliso-V, but has a proprietary Topo-1 warhead to afford deeper and more durable responses with an improved therapeutic index. We remain on track to see data...
ABBV-400, where the emerging clinical data is very promising in several solid tumors. This asset is similar to Teliso-V, a c-MET ADC that uses a microtubule inhibitor payload. Teliso-V received breakthrough therapy designation for the treatment of patients with a subtype of lung cancer with ...
Clinical Trial 分子量 459.47 Formula C22H19F2N3O4S CAS 号 1445993-26-9 中文名称 米维布塞 运输条件 Room temperature in continental US; may vary elsewhere. 储存方式 溶解性数据 In Vitro: DMSO : 100 mg/mL(217.64 mM;Need ultrasonic) 配制储备液 ...
(an MCL-1 inhibitor) and could promote apoptosis. In animal models, ABBV-467 led to cancer cell death and delayed tumor growth. ABBV-467 was also studied in a clinical trial in 8 patients with multiple myeloma, a blood cancer. In 1 patient, ABBV-467 treatment prevented the cancer from ...
Enrollment was initiated in November 2023, with 3 patients enrolled as of January 4, 2024.Clinical trial information: NCT06107413.Kanwal Pratap Singh RaghavThe University of Texas MD Anderson Cancer Center, Houston, TXAyala HubertHadassah Medical Center, Kiryat Hadassah, Jerusalem, IsraelMarwan Fakih...
the 2.4 mg/kg Q3W dosing regimen provides an optimal balance of safety and efficacy compared to 3.0 mg/kg Q3W.Conclusions:Population PK, E-R for efficacy and safety and RDI analyses and totality of clinical data supported the selection of 2.4 mg/kg Q3W as optimal ABBV-400 monotherapy dose ...
ABBV-400 is an antibody-drug conjugate, consisting of the c-Met–targeting antibody telisotuzumab conjugated to a potent topoisomerase 1 inhibitor payload. Initial results from the ongoing first-in-human study (NCT05029882) of ABBV-400 in patients with advanced solid tumors indicate a tolerable ...